gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Peptilogics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLG0206

            Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 09, 2020

            Details:

            PLG0206 is the first novel anti-infective to be granted Orphan Drug Designation, confirmation that we are advancing a meaningful therapy that can address an unmet medical need, beginning with PJI.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLG0206

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: CARB-X

            Deal Size: $12.1 million Upfront Cash: Undisclosed

            Deal Type: Funding February 25, 2020

            Details:

            The funding will help Peptilogics to advance its PLG0206 through Phase 1 clinical studies for its first indication of prosthetic joint infections (PJI).